Moderna Inc said on Monday that its COVID-19 vaccine generated an immune response and was generally well-tolerated in children aged six to 11 years, citing interim data from a study.

(Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manasmishra24; within U.S. +1 646 223 8780, outside U.S. +91 806749 2709))